SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced that it will deliver three presentations at the American Society of Nephrology Kidney Week 2024 annual meeting taking place in San Diego, California, October 23-27, 2024..

加利福尼亚州南旧金山——（商业新闻短讯）——SonoThera™是一家致力于通过基因疗法治疗人类疾病根本原因的生物技术公司，今天宣布，它将在2024年10月23日至27日于加利福尼亚州圣地亚哥举行的2024年美国肾脏病学会肾脏周年会上发表三篇演讲。。

Each presentation features SonoThera’s novel, ultrasound-mediated nonviral gene therapy platform, which is being developed to non-invasively deliver nucleic acid payloads of diverse formats and sizes. While the platform is designed to selectively target a wide range of organs within the body, research presented at ASN Kidney Week focuses on its potential in the treatment of X-linked Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease, and its targeted delivery of re-dosable DNA payloads resulting in robust and durable gene expression in podocytes and tubule epithelial cells in the kidneys of murine and NHP models..

每次演讲都以SonoThera的新型超声波介导的非病毒基因治疗平台为特色，该平台正在开发中，以无创地提供不同形式和大小的核酸有效载荷。虽然该平台旨在选择性靶向体内广泛的器官，但在ASN肾脏周上进行的研究侧重于其在治疗X连锁Alport综合征和常染色体显性多囊肾病方面的潜力，以及其靶向递送可重复给药的DNA有效载荷，从而在小鼠和NHP模型的肾脏足细胞和小管上皮细胞中产生强大而持久的基因表达。。

“Taken together, these three abstracts demonstrate the potential which targeted, nonviral, ultrasound-mediated gene therapy can offer in diseases where presently, we have some of the greatest challenges in finding effective treatments. We look forward to presenting our results at ASN Kidney Week.” said Kenneth Greenberg, PhD, CEO of SonoThera, who will be presenting the Company’s session focused on nonviral gene therapy for X-linked Alport Syndrome..

“综上所述，这三篇摘要展示了靶向、非病毒、超声波介导的基因治疗在疾病中的潜力，目前，我们在寻找有效治疗方法方面面临着一些最大的挑战。我们期待着在ASN肾脏周上展示我们的结果。”SonoThera首席执行官肯尼斯·格林伯格博士表示，他将出席该公司针对X连锁Alport综合征的非病毒基因治疗会议。。

Session Details:

会话详细信息：

Title: Development of a Nonviral Gene Therapy for X-linked Alport Syndrome by Targeted Transcutaneous Ultrasound-Mediated Gene Delivery

标题：通过靶向经皮超声介导的基因传递开发X连锁Alport综合征的非病毒基因疗法

Presenter: Kenneth Greenberg, PhD, CEO of SonoThera

主持人：肯尼斯·格林伯格博士，SonoThera首席执行官

Session Category: 1201 Genetic Diseases of the Kidneys: Cystic - Non-Cystic Genetic Kidney Diseases: Disease Genes, Modifiers, and Therapies

课程类别：1201肾脏遗传性疾病：囊性-非囊性遗传性肾脏疾病：疾病基因，修饰剂和疗法

Session Date/Time: Thursday, October 24, 5:50pm – 6:00pm, Room 23, Convention Center

Session Date/Time: Thursday, October 24, 5:50pm – 6:00pm, Room 23, Convention Center

Abstract Number: TH-OR90

摘要编号：TH-OR90

Title: Development of a Nonviral Genetic Medicine for ADPKD Administered through Targeted Transcutaneous Ultrasound-Mediated Delivery

标题：通过靶向经皮超声介导的递送给药的ADPKD非病毒遗传药物的开发

Presenter: Margot Krivega, PhD

主持人：Margot Krivega博士

Session Category: 1201 Genetic Diseases of the Kidneys: Cystic - Cystic Kidney Diseases: Clinical Assessment and Therapeutic Directions

课程类别：1201肾脏遗传性疾病：囊性-囊性肾脏疾病：临床评估和治疗方向

Session Date/Time: Thursday, October 24, 10:00am – 12:00pm, Exhibit Hall, Convention Center

会议日期/时间：10月24日星期四上午10:00–下午12:00，会议中心展览厅

Abstract Number: TH-PO431

摘要编号：TH-PO431

Title: Kidney-Targeted Delivery of Nonviral Nucleic Acids Using Noninvasive Transcutaneous Ultrasound Enables Safe, Re-dosable, Titratable, and Durable Gene Expression in Mice and Nonhuman Primates

标题：使用无创经皮超声波以肾脏为靶向递送非病毒核酸，可在小鼠和非人灵长类动物中实现安全，可重复给药，可滴定和持久的基因表达

Presenter: Burt Frederich, PhD

主持人：伯特·弗雷德里克博士

Session Category: 1201 Genetic Diseases of the Kidneys: Cystic - Cystic Kidney Diseases: Clinical Assessment and Therapeutic Directions

课程类别：1201肾脏遗传性疾病：囊性-囊性肾脏疾病：临床评估和治疗方向

Session Date/Time: Thursday, October 24, 10:00am – 12:00pm, Exhibit Hall, Convention Center

会议日期/时间：10月24日星期四上午10:00–下午12:00，会议中心展览厅

Abstract Number: TH-PO432

摘要编号：TH-PO432

About SonoThera™

关于索诺Thera™

Founded by Drs. Kenneth Greenberg, Michael Davidson, and Steve Feinstein, SonoThera, Inc. is a biotechnology company dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-mediated, nonviral gene therapy platform treatments designed to provide patients with the next generation of safe and effective genetic medicines.

SonoThera，Inc.是一家生物技术公司，由肯尼斯·格林伯格（KennethGreenberg）博士、迈克尔·戴维森（MichaelDavidson）和史蒂夫·范斯坦（SteveFeinstein）创建，致力于通过基因治疗来治疗人类疾病的根本原因。SonoThera正在开发一种超声波介导的非病毒基因治疗平台，旨在为患者提供下一代安全有效的基因药物。

The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. SonoThera is headquartered in South San Francisco, California. Visit www.sonothera.com to learn more..

该平台利用声孔技术（一种微泡介导的生物物理过程）非侵入性地传递遗传有效载荷，选择性地靶向体内多种器官。。访问www.sonothera.com了解更多信息。。